Open AccessTargeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study
Author(s) -
Lili Guo,
Jiaping Zheng,
Jun Luo,
Zhewei Zhang,
Guoliang Shao
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s249412
Subject(s) - gene knockdown , yap1 , sorafenib , cancer research , cell growth , epithelial–mesenchymal transition , apoptosis , oncogene , viability assay , hepatocellular carcinoma , cell culture , transfection , downregulation and upregulation , cell , hippo signaling pathway , carcinogenesis , biology , chemistry , medicine , metastasis , cell cycle , cancer , transcription factor , biochemistry , genetics , gene
The aim of this study was to investigate the role of Yes1 associated transcriptional regulator (YAP1) in the pathology of hepatocellular carcinoma (HCC) and its potential as a therapeutic target.